EVP & Chief Scientific Officer · Vertex Pharmaceuticals Inc (VRTX)

David Altshuler

A named executive officer of Vertex Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$7,637,478

Salary $876,443Stock awards $5,250,328

FY2023: $6,541,100

4th of 5 named executive officers at Vertex Pharmaceuticals by FY2024 total.

5 named officers on file for Vertex Pharmaceuticals, FY2024

David Altshuler’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • VRTX’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get David Altshuler’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Altshuler compensation by year

Vertex Pharmaceuticals Summary Compensation Table · all 4 fiscal years held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2022FY2023FY2024
Salary$752,885$810,577$825,000$876,443
Bonus$0$0—$0
Stock awards$5,250,411$4,500,090$4,375,089$5,250,328
Option awards$0$0—$0
Non-equity incentive$1,015,508$1,172,325$1,299,375$1,456,920
Pension and deferred compensation$0——$0
All other$41,780$42,137$41,636$53,787
Total$7,060,584$6,525,129$6,541,100$7,637,478

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 3, 2025, accession 0000875320-25-000160, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0000875320-25-000160. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2025.

$7.1M
$6.5M
$6.5M
$7.6M
FY20
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU12,314$4,958,848—
RSU7,866$3,167,638—
PSU7,114$2,864,808—
RSU7,114$2,864,808—
RSU7,114$2,864,808—
RSU7,114$2,864,808—
RSU5,244$2,111,759—
RSU4,106$1,653,486—
RSU4,105$1,653,084—

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2024 proxy (filed April 3, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-22Grant or award—3,328$0.0034,477
2026-01-22Grant or award—7,866$0.0031,149
2025-05-15Sale10b5-152$424.6923,281

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Vertex Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Reshma KewalramaniCEO and President$21,538,668
Stuart ArbuckleEVP & Chief Operating Officer$9,383,463
Charles WagnerEVP & Chief Financial Officer$7,999,440
David Altshuler · this pageEVP & Chief Scientific Officer$7,637,478
Nia TatsisEVP & Chief Regulatory and Quality Officer$7,334,316

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Altshuler's compensation dossier · One-time report. No refunds.